Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02252263 |
| Title | A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Bristol-Myers Squibb |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ESP |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University Of Arkansas For Medical Sciences | Little Rock | Arkansas | United States | Details | ||
| The Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | United States | Details | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
| The Ohio State University | Columbus | Ohio | 43210 | United States | Details | |
| Oregon Health & Science University | Portland | Oregon | 97239 | United States | Details | |
| University Of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States | Details | |
| Local Institution | Pamplona | Navarra | 31008 | Spain | Details |